Ravi Kumar Dalai
About Ravi Kumar Dalai
Data last updated:
Ravi Kumar Dalai is a Director at Cpr Laboratories Private Limited (since 2016). The companies operate in Pharma. Cpr Laboratories Private Limited reported revenue of ₹4.86 Cr (FY 2020). Earlier, Ravi Kumar Dalai was a Director at Jasmine Healthcare India Private Limited (from 2017).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Cpr Laboratories Private Limited U24100AP2016PTC098502 | Director | 11 Mar 2016 | 2016 | ₹4.86 Cr (FY 2020) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Jasmine Healthcare India Private Limited U74999AP2017PTC105406 | Director | 15 Mar 2017 | 2017 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Ravi Kumar Dalai
| Name | DIN | Company | Designation |
|---|---|---|---|
| Vijayakumar Dalai | 07599471 | Cpr Laboratories Private Limited | Nominee |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Ravi Kumar Dalai
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ravi Kumar Dalai
Ravi Kumar Dalai currently holds 1 directorship: Cpr Laboratories Private Limited (Director, since 11 Mar 2016, revenue ₹4.86 Cr (FY 2020)).
Ravi Kumar Dalai was first appointed on 11 Mar 2016 as Director at Cpr Laboratories Private Limited. The most recent appointment on record is 15 Mar 2017 at Jasmine Healthcare India Private Limited.
Ravi Kumar Dalai held 1 earlier board appointment: Jasmine Healthcare India Private Limited (Director, from 15 Mar 2017).
The current boards of Ravi Kumar Dalai's companies include Vijayakumar Dalai (Cpr Laboratories Private Limited).